Dr. Kreshnik Zejnullahu, MD

Dr. Zejnullahu practices at UCSF St Mary's Hospital in San Francisco, California.

Dr. Zejnullahu's NPI, 1326465444, was assigned on March 26, 2014. Dr. Zejnullahu graduated from University of Massachusetts Medical School in 2014. Dr. Zejnullahu's California license number on file is A140878.

Dr. Zejnullahu's primary practice is UCSF St Mary's Hospital, at 450 Stanyan St, San Francisco, CA 94117 in San Francisco County. The practice phone is (415) 353-4739.

Dr. Zejnullahu's primary practice is UCSF St Mary's Hospital in San Francisco, California. Dr. Zejnullahu is also affiliated with UCSF Helen Diller Medical Center at Parnassus Heights. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Zejnullahu to 1 more hospital, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zejnullahu practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Zejnullahu's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Zejnullahu is board certified in internal medicine by the American Board of Internal Medicine. Dr. Zejnullahu has a license on file in California.

Dmand AI lists acute diabetes, cardiac arrhythmia, cellulitis, chronic inflammatory bowel disease (IBD), chronic kidney disease, circulatory problems in extremities, electrolyte disorders and gastrointestinal bleeding among the conditions Dr. Zejnullahu treats.

CMS data shows 307 Medicare services from Dr. Zejnullahu across 5 procedure codes in 2024, for 88 Medicare patients. Medicare paid $25,979 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 88 Medicare patients who saw Dr. Zejnullahu in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 58% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zejnullahu's median patient age at 72, with 40% women.

In 2024, Dr. Zejnullahu wrote 73 Medicare Part D claims for 30 patients. 77% of them were for generic drugs. CMS names the drug for 23 of them, across 2 drugs with 11 or more claims each, at $320 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Zejnullahu for performance year 2024, reported as part of a group. Dr. Zejnullahu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 23 papers to Dr. Zejnullahu, published from 2006 to 2020. 2012 was the busiest year, with 4. The most frequent topics are Cell Line, Tumor, Lung Neoplasms and Drug Resistance, Neoplasm. Dr. Zejnullahu has published most often in Cancer Res. Dr. Zejnullahu's most frequent co-authors are Rahul R. Aggarwal, MD, Michelle Sarah Mourad, MD and Lekshmi Santhosh, MD.

CMS Open Payments shows 1 general payment to Dr. Zejnullahu from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Mallinckrodt LLC paid the most, $15.

Dr. Zejnullahu graduated from University of Massachusetts Medical School in 2014.

Dr. Zejnullahu is in network with 5 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.